Results with Lifescozul™Leukaemia
Introduction to the case
Leukemias are cancers that we do not like to treat. It is true that we have treated few cases, no more than 15 in the last 14 years, and in many of them we have observed that the quality of life improves, but we do not achieve that the disease as such has a response to treatment.
This is due to the type of cells and their location.
Leukemia has several types that are divided based on their growth: rapid or chronic (slower growth), and whether it starts in myeloid cells or lymphoid cells.
The case we will see today is a Chronic Myeloid Leukemia (CML) and its entry into the LifEscozul Protocol occurs at the personal request of the patient despite our refusal given the previous results.
Our initial objective was to provide quality of life, but the results far exceeded our expectations.
Gloria Lucía Oviedo Cabrera, 72 years old at the beginning of treatment with LifEscozul.
Depression, asthenia, fatigue, loss of strength.
January 24, 2019.
Chronic Myeloid Leukemia (CML).
Gloria was diagnosed with CML in 2011, and was kept under control until mid-2018, when her blood parameters began to show alterations.
She came to LifEscozul, the most effective formulation made with blue scorpion venom, in January 2019 looking for another treatment option for her disease, as at that time nothing was working for her and her quality of life was deteriorating rapidly.
Gloria in describing her symptoms commented that she generally felt very bad, with very difficult periods of 3 or 4 days in which she presented a very great tiredness, had no strength to move, spent almost all her time lying down and depended on her daughter to feed her.
Evolution with LifEscozul™ and actual results
When the case was evaluated by our Medical Committee, we explained to Gloria the need for constant contact and dose adjustment, as her case was very uncertain for us.
Gloria began to report that her days began to gradually improve and her symptoms began to fade and recede, until she began to maintain a much higher quality of life.
This is important as it is a clear indicator that the LifEscozul Protocol was beginning to work.
First Quarterly Cycle Summary: April 2019
Upon completing the first 3 months of treatment we proceeded to assess with Gloria her clinical evolution during this period, in terms of quality of life and test results.
With LifEscozul, Gloria recovered her quality of life in such a way that she commented to us that she felt very well, that she could do almost everything at home by herself, slowly and without exaggeration, she could go out for a walk with her daughter and granddaughter, she no longer had to sit on a bench without moving because she was already walking too, without overdoing it of course. She went back to hanging out with her friends and driving her car, sometimes she felt tired but not like before and every day she was feeling better and happier.
Blood tests showed a marked improvement over the previous 3 months.
(put comparative pictures)
September 2019 (8 months on LifEscozul treatment).
By September Gloria was walking 3.5 kilometers daily and reported feeling well.
The results sent by Gloria reflected that the blood values or indicators referring to the presence of CML had decreased considerably.
The disease was totally controlled, maintaining her quality of life and with her indicators almost normal.
In June 2020
By June 2020 blood tests the disease was fully controlled and Gloria was fully independent, with a tremendous quality of life and granting us the opportunity to tell her story.
When a case of Leukemia comes to us we always explain that, because of the cell type, the effect of the treatment is much smaller and unlikely to have a positive impact. We are of the opinion that false expectations are unacceptable.
However, Gloria decided to give it a try and in her case the result obtained with the LifEscozul treatment (the most effective formulation ever developed with Blue Scorpion Venom) has been spectacular.
Gloria went from having zero quality of life, hopeless and with a disease in progression, to recovering her quality of life, to depending on herself and above all to controlling her disease completely.
It is a tremendous result, where the merit lies in Gloria's courage to try despite the odds against her.
This teaches us that we should never give up.
We are the LifEscozul Group and Results Define Us.
Breast cancer is the most common cancer among women and is the second leading cause of death from cancer. View more